<DOC>
	<DOCNO>NCT01861561</DOCNO>
	<brief_summary>Proliferative lupus nephritis ( LN ) predominant cause morbidity mortality juvenile Systemic Lupus Erythematosus ( SLE ) . Induction therapy high-dose intravenous cyclophosphamide improve renal outcome , considerably associate infection . Although severe infection significant complication relate poor prognosis juvenile SLE patient Asia , cyclophosphamide still commonly use drug choice severe lupus nephritis . Euro-Lupus Nephritis Trial demonstrate low-dose intravenous cyclophosphamide regimen follow azathioprine achieve good clinical result comparable obtained high-dose regimen . There low number severe infection episode , significant difference . Recent study apply low dose cyclophosphamide ( 500 mg/m2/dose 500 mg/dose ) young patient show good renal response . Low-dose intravenous cyclophosphamide regimen might promote non-inferior renal remission whereas decrease risk serious infection improve overall patient outcome .</brief_summary>
	<brief_title>Low-dose VS High-dose IV Cyclophosphamide Proliferative LN Children</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Child 15 year age fulfil 1997 updating American College Rheumatology revise criterion classification SLE renal biopsy reveals lupus nephritis class III IV regard International Society Nephrology/Renal Pathology Society revision classification lupus nephritis . patient prior renal insufficiency due chronic kidney disease lupus nephritis patient history cyclophosphamide hypersensitivity patient prior cyclophosphamide mycophenolate mofetil administration within 6 month patient pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>